See What's Possible. Feel What's Possible.
DUPIXENT was studied in a 16-week clinical trial with 251 patients* ages 12-17 with
moderate-to-severe eczema not adequately controlled with topical prescription treatments.
Results from a 16-week clinical trial of teens ages 12-17 with DUPIXENT when used alone compared to teens not taking DUPIXENT
12X more teens saw clearer skin
(24% vs 2% in those not taking
75% skin improvement in nearly half of
teens, and some even saw 90%
improvement (42% vs 8% in those not
taking DUPIXENT and 23% vs 2% not
taking DUPIXENT, respectively)
7X more teens experienced itch relief
(37% vs 5% in those not taking
The safety results of DUPIXENT observed in adolescents were consistent with what was seen in adults
with atopic dermatitis. The most common side effects include injection site reactions, eye and eyelid
inflammation, including redness, swelling, and itching, and cold sores in your mouth or on your lips.
*Patients who weighed ≥60 kg received DUPIXENT 300 mg every two weeks after an initial dose of 600 mg (two 300 mg injections),
and patients who weighed ≤60 kg received DUPIXENT 200 mg every two weeks after an initial dose of 400 mg (two 200 mg injections)
What You Should Know About the Patients in This Study:
had moderate atopic dermatitis
had severe atopic dermatitis
Average body surface area involvement
Had at least one other allergic condition
GET DOWN TO THE DETAILS
Expand the boxes below to see more detailed results from the clinical study with patients ages 12-17.